Intraoperative Radiation Allows Lumpectomy Patients to Skip Boost

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

TOLEDO, Ohio-Researchers at the Medical College of Ohio have treated a series of breast-conservation patients with intraoperative electron beam radiation to the tumor bed, in conjunction with a course of 45 to 50 Gy of external beam radiation.

TOLEDO, Ohio—Researchers at the Medical College of Ohio have treateda series of breast-conservation patients with intraoperative electron beamradiation to the tumor bed, in conjunction with a course of 45 to 50 Gyof external beam radiation.

With this technique, "you can eliminate the boost dose at the endof radiation therapy, thus shortening the course of external beam radiationby eight days," Joyce A. Battle, MD, assistant professor of radiationtherapy, said in her poster presentation.

The study began in 1984 under the auspices of Ralph R. Dobelbower, MD,PhD, chairman, Department of Radiation Therapy. Dr. Battle reported onthe first 21 patients, all with stage I and II disease, and ranging inage from 33 to 75 years. "There have been no local recurrences withthis treatment, with follow-up of 11 years," Dr. Battle said. Twopatients have died of distant disease, including the youngest patient,whose disease was very virulent, and one patient has been lost to follow-up.

The Ohio team has now treated 25 patients with intraoperative radiationat a dose of 10 or 15 Gy. Said Dr. Battle: "Our center and a centerin Montpellier, France, are the only two that I know of that are doingintraoperative boost radiation to the tumor bed for early-stage conservativetreatment."

The technique requires a surgeon who is willing to work in the intraoperativeradiotherapy suite. "Dr. H. W. Merrick has performed all but two ofthese procedures," she said, "but with the recent addition ofanother surgical oncologist, we may do more."

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content